Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 5Breast 3Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 243Neoplasms 15Neoplasm Metastasis 12Carcinoma, Intraductal, Noninfiltrating 11Breast Diseases 8Advanced Breast Cancer 8Breast Neoplasms, Male 7Breast Carcinoma In Situ 7Triple Negative Breast Neoplasms 5Arthralgia 4Ovarian Neoplasms 3Neoplasms by Site 3Breast Cancer Metastatic 3Uterine Cervical Neoplasms 2Recurrence 2Patient Compliance 2Osteoporosis 2Obesity 2Endometrial Neoplasms 2Breast Neoplasm Female 2Vitamin D Deficiency 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pain 1Nutrition Disorders 1

Interventions

pembrolizumab 42Paclitaxel 26Cyclophosphamide 25Carboplatin 23olaparib 21Nivolumab 16fludarabine 15Docetaxel 13aldesleukin 12Gemcitabine 11Fulvestrant 11veliparib 9Bevacizumab 9sargramostim 8palbociclib 8durvalumab 8Trastuzumab 8Magnetic Resonance Spectroscopy 8liposomal doxorubicin 7atezolizumab 7Surveys and Questionnaires 7Ipilimumab 7Blood Specimen Collection 7niraparib 6avelumab 6Taxes 6Specimen Handling 6Interleukin-2 6Fluorouracil 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Anastrozole × Breast × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡